A new Nature Cancer study reveals a sex-specific immune mechanism in glioblastoma, showing that the neurotransmitter GABA reprograms granulocytic myeloid-derived suppressor cells (MDSCs) only in female models, driving tumor growth and immunosuppression.

Blocking GABA signaling in female models reduces MDSC-mediated immunosuppression and improves survival, an effect not seen in male models, pointing to potential sex-targeted therapies.

Validation in human tumors indicates higher GABA and GABA receptor expression on granulocytic MDSCs in female patients, underscoring the clinical relevance of the preclinical sex differences.

The study was led by Defne Bayik at the University of Miami’s Sylvester Comprehensive Cancer Center and published in Nature Cancer, with related commentary and institutional context."

These findings advocate incorporating sex as a biological variable in cancer research and precision oncology, potentially extending to other cancers where MDSCs play a role.

Because suppressive MDSCs are involved across cancer types, the observed sex-specific metabolism could inform targeted treatments beyond glioblastoma.

The research connects to a broader effort to understand how sex differences influence tumor biology and treatment responses, offering a framework for more personalized approaches.